Craig W. Philips Takes Helm at CTI (y operations with salesof $350 million a...)

Craig W. Philips Takes Helm at CTI

Date:8/4/2008

y operations with sales of $350 million and a staff of over 150. Philips was also either a member or chair of alliance executive committees which included Onyx, Novartis, Genzyme, and Favrille.

Prior to Bayer Healthcare, Philips was the head of Berlex Oncology since 2004. He was responsible for the U.S. oncology operations with sales of over $160 million. Before Berlex, Philips was with Schering Plough in U.S., and international roles. He began his career with Bristol Myers, where he worked in a variety of therapy areas including oncology, cardiology, and CNS.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non- Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-nave, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment)
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. Queen Latifahs Travlin Light Tour to Be Sponsored by Jenny Craig
2. Cooper Clinic at Craig Ranch Opens Signaling the Next Phase of CooperLife Health-Focused Residential Community in McKinney
3. Jenny Craig Offers Help to Stranded Clients
4. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
5. Cardinal Health Names Former Acting Deputy U.S. Attorney General Craig S. Morford to Chief Compliance Officer Post
6. J. Craig Venter, Human Genome Pioneer, to Receive Award at Vietnam Veterans of Americas National Leadership Conference
7. Jenny Craig Establishes License Agreement for Volumetrics(R)
8. VASAMED(R) Appoints Craig M. Walker, MD to Board of Directors
9. MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners
10. Audio from Medialink and Philips: Americas Dirty Mouths
11. AUDIO from Medialink and Philips: Getting Rid of the Uninvited Holiday Guests on Your Toothbrush

Post Your Comments:

Craig W. Philips Takes Helm at CTI(y operations with salesof $350 million a...),Health